Our second Health Technology Assessment and Evidence Synthesis Bulletin of 2024 is out now. It provides a brief summary of our key activities and achievements for the second quarter of the year, including our latest reports, as well as work we’ve recently undertaken; conferences at which we’ve presented; and academic publications. Key reports include:

• A public consultation on our draft HTA on the use of an enhanced inactivated influenza (flu) vaccine in those aged 65 years and older.
• Approval of the use of ¹⁷⁷Lutetium PSMA radioligand therapy for the treatment of metastatic castrate-resistant prostate cancer.
• An evidence review report on universal ultrasound screening for developmental dysplasia of the hip in infants in Ireland.
• A HTA studying the value of screening for abdominal aortic aneurysm in men.
• Our HTA Knowledge Sharing and Impact Assessment Report for 2023.

Subscribe to receive future issues directly to your inbox at htanews@hiqa.ie.